Radiochemotherapy in Elderly Patients With Oesophagus Cancer
NCT ID: NCT02879227
Last Updated: 2016-08-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
23 participants
INTERVENTIONAL
2010-01-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chemoradiotherapy in Elderly Patients With Oesophagus Cancer
NCT02735057
CCRT for Esophageal Cancer.
NCT02607982
A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer
NCT01843829
Chemoradiotherapy in Unresectable Esophageal Cancer
NCT04278287
Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
NCT02636088
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm Cisplatin
Radiotherapy 50 Gy with cisplatin 75 mg/2 Day 1 and day 22 (2)
Cisplatin
Arm cisplatin : 75mg/m2, day n\*1 and day n\*22, And radiotherapy 50 Gy, 2Gy/f
Arm Oxaliplatin
Radiotherapy 50Gy Oxaliplatin 85mg/m2 every 2 weeks, (6)
Oxaliplatin
85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cisplatin
Arm cisplatin : 75mg/m2, day n\*1 and day n\*22, And radiotherapy 50 Gy, 2Gy/f
Oxaliplatin
85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* no fit to treat
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Besancon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
References
Explore related publications, articles, or registry entries linked to this study.
Servagi-Vernat S, Bosset M, Crehange G, Buffet-Miny J, Puyraveau M, Maingon P, Mercier M, Bosset JF. Feasibility of chemoradiotherapy for oesophageal cancer in elderly patients aged >or=75 years: a prospective, single-arm phase II study. Drugs Aging. 2009;26(3):255-62. doi: 10.2165/00002512-200926030-00006.
Servagi-Vernat S, Crehange G, Roullet B, Guimas V, Maingon P, Puyraveau M, Bosset JF. Phase II Study of a Platinum-Based Adapted Chemotherapy Regimen Combined with Radiotherapy in Patients 75 Years and Older with Esophageal Cancer. Drugs Aging. 2015 Jun;32(6):487-93. doi: 10.1007/s40266-015-0275-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P/2009/79
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.